TransCode Therapeutics Announces Leadership Transition
Stocks in this Quantisnow insightHealth Care
Historical context for RNAZ
Across the 13 sessions after earlier RNAZ headlines, the stock closed higher 5 times and lower 7 times, with a median move of 3.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | RNAZ | SPY |
|---|---|---|---|
| Aug 31, 2026 | TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis | -3.7% | -0.3% |
| Jun 8, 2026 | TransCode Therapeutics to Host R&D Webcast on June 18, 2026 | -9.1% | +0.2% |
| Jun 3, 2026 | TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer | -4.6% | -0.7% |
| May 27, 2026 | TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer | -5.6% | -0.0% |
| Apr 27, 2026 | TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University | +0.0% | +0.2% |
| Apr 7, 2026 | TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 | -2.9% | +0.0% |
Quantisnow market dataNASDAQ
RNAZ
TransCode Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for RNAZ
Full RNAZ profile on Quantisnow Follow RNAZ and get a push notification the moment its next story breaks.